期刊文献+

结直肠癌新辅助化疗前后CEA变化的影响因素分析 被引量:1

暂未订购
导出
摘要 目的研究结直肠癌新辅助化疗前后CEA变化的影响因素。方法回顾性分析2014年6月至2016年7月郑州大学第一附属医院、中山附院大肠癌医院、新疆维吾尔自治区中医院接受新辅助化疗的218例结直肠癌患者的临床资料,检测新辅助化疗前后患者血CEA水平,根据血CEA水平将患者分为CEA变化组(57例,化疗前后CEA下降≥5.5 ng/ml)和CEA不变/微变化组(161例,化疗前后CEA下降<5.5 ng/ml),应用Logistic回归分析新辅助前后结直肠患者血清CEA变化的影响因素。结果单因素分析:新辅助前后血清CEA变化与肿瘤浸润深度、CA199水平、神经侵犯、分化程度、远处转移、肛距具有相关性(均P<0.05);多因素分析:肿瘤浸润深度、CA199水平、远处转移是结直肠癌新辅助化疗前后CEA变化的独立预测因素(均P<0.05)。结论肿瘤浸润深度、CA199水平、远处转移是结直肠癌新辅助化疗前后CEA变化的独立预测因素。
作者 朱浩 袁伟堂
出处 《河南医学研究》 CAS 2018年第8期1397-1399,共3页 Henan Medical Research
  • 相关文献

参考文献6

二级参考文献59

  • 1Baxter NN,Morris AM,Rothenberger DA,et al.Impact of preoperative radiation for rectal cancer on subsequent lymph node evaluation:A population-based analysis.Int J Radiat Oncol Biol Phys,2005,61:426-431.
  • 2Wanebo HJ,Rao B,Pinsky CM,et al.Preoperative carcinoembryonic antigen level asa prognostic indicator in colorectal cancer.N Engl J Med,1978,299:448-451.
  • 3Fletcher RH.Carcinoembryonic antigen.Ann Intern Med,1986,104:66-73.
  • 4Seya T,Tanaka N,Shinji S,et al.Lumican expression in advanced colorectal cancer with nodal metastasis correlates with poor prognosis.Oncol Rep,2006,16:1225-1230.
  • 5National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology:colon cancer.V.2.2011.http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
  • 6National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology:rectal cancer.V.2.2011.http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf.
  • 7Edge SB,Byrd DR,Compton CC,et al.AJCC Cancer Staging Manual.7th ed.New York:Springer,2010.
  • 8Van Custem E,Lang,I,Folprecht G,et al.Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC):The influence of KRAS and BRAF biomarkers on outcome:Updated data from the CRYSTAL trial.ASCOGastrointestinal Cancer Symposium,2010:abstract 281.
  • 9Di Nicolantonio F,Martini M,Molinari F,et al.Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.J Clin Oncol,2008,26 (35):5705 -5712.
  • 10Bokmeyer C,Kohne C,Rougier C,et al.Cetuximab with chemotherapy as first-line treatment for metastatic colorectal cancer:Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation analysis.J Clin Oncol,2010,28suppl 15:abstract 3506.

共引文献604

同被引文献8

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部